In 2019, three M & A cases of pharmaceutical enterprises with a transaction value of more than 1 billion

[industry trends of pharmaceutical network] in 2019, with the promotion of policies such as the nationwide spread of volume procurement, the dynamic adjustment of medical insurance catalog, financial and tax verification, and the encouragement of innovation, China's pharmaceutical industry has intensified the reshuffle, the industrial concentration has further improved, and the popularity of Bio innovative drugs has increased At the same time, the pace of merger and reorganization of pharmaceutical enterprises is also accelerating Many large pharmaceutical companies regard M & A as an important way to expand R & D pipeline and realize scale expansion According to the comprehensive factors such as the transaction amount, the decision-maker and the target's influence in the industry, some industry researchers selected representative cross-border M & A cases in the field of medicine and health in 2019 (as of December 31, 2019, the transaction status is delivery, signing and announcement), involving pharmaceutical enterprises such as Shanghai Laishi, Yiteng pharmaceutical, lanfan medical, Jiuzhou, Yifan medical, etc The author combs out the cases with the transaction amount of more than 1 billion yuan, which is only for the reference of the industry Transaction amount of GDS acquisition by Shanghai Laishi: 13.246 billion yuan The plan of GDS acquisition by Shanghai Laishi has undergone significant adjustment It was planned to acquire all or part of the equity of GDS and 100% equity of Tiancheng Germany with 39.114 billion yuan However, after the announcement of the acquisition plan, the share price of Shanghai Laishi declined significantly, which made it difficult to continue to promote the acquisition plan of GDS in the plan After the adjustment, it was changed into Shanghai Laishi's acquisition of 45% of the GDS held by keelford with 13.246 billion yuan, and the transaction price was reduced by 25.868 billion yuan According to the public information, GDS is a subsidiary of global well-known blood products enterprise, which belongs to the in vitro diagnosis industry and blood testing industry Its main products include nucleic acid detection instruments and reagents, immune antigens and blood group detection instruments and reagents The industry believes that with the further cooperation and integration with GDS, Shanghai Laishi will form a complementary relationship with GDS in the existing customer resources and sales channels to achieve effective business integration The transaction amount of two antibiotic products and factories acquired by Yiteng Pharmaceutical Co., Ltd.: 2.588 billion yuan In April 2019, Yiteng Pharmaceutical Co., Ltd signed an agreement with Lilly, a US pharmaceutical company, to acquire two antibiotic products sold by Lilly in China, i.e Ceclor ® and vanocin ®, as well as the production plant in Suzhou, China It is worth mentioning that Yiteng pharmaceutical has obtained the promotion and distribution rights of the above two classic anti infective drugs in mainland China since 2017 In August 2019, the hickory ® production plant involved in the transaction was officially renamed as cicro Pharmaceutical Co., Ltd Through the acquisition of the whole industry chain, Yiteng pharmaceutical will further improve the ability of the whole industry chain, especially with the official unveiling of xikro company, which means that the development of Yiteng pharmaceutical has entered a new stage It is reported that Yiteng medicine will continue to focus on anti infection, Patients with respiratory disease treatment, anti-tumor and cardiovascular disease treatment need huge disease areas Lanfan medical acquired NVT with transaction amount of 1.39 billion yuan In the evening of October 13, 2019, lanfan medical planned to acquire new valve, a Swiss heart valve R & D and production enterprise Technology (hereinafter referred to as "NVT") has 100% equity, and the total consideration for acquisition and subsequent capital increase is RMB 1.39 billion The acquisition means that blue sail medical will enter the promising field of minimally invasive heart disease treatment According to the data, NVT is a medical device company focusing on the field of heart valve Its core product is TAVR system Allegra, which mainly treats aortic valve stenosis The industry believes that TAVR has become a golden track for medical device giants Lanfan medical's M & A integration ability is better than expected As TAVR is incorporated into the company's high-value consumables industry layout, it will bring strong and predictable performance growth points for the development of lanfan medical in the field of high-level medical devices.